Publications by authors named "V Cabanas"
Multiple myeloma (MM) remains incurable, with poor outcomes in heavily pre-treated patients with plasmacytomas. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment option; however, outcomes after such therapy in patients with soft-tissue plasmacytomas and other bone lesions remain poorly understood. Data regarding these parameters is scarce within the specific context of CAR T-cell treatment.
View Article and Find Full Text PDFArticle Synopsis
- - In a study of 138 multiple myeloma (MM) patients, researchers explored the benefits of monitoring peripheral residual disease (PRD) in blood instead of relying solely on more invasive bone marrow (BM) assessments.
- - Positive PRD results from next-generation flow (NGF) indicated a significantly higher risk of disease progression/death, and those with undetectable PRD had excellent survival rates.
- - The findings suggest that PRD monitoring is a valuable and less cumbersome method for identifying patients at risk of relapse during maintenance treatment in transplant-eligible MM patients.
Quantitative immunoprecipitation mass spectrometry (QIP-MS) allows the identification of the M-protein in patients with multiple myeloma (MM) otherwise in complete response, and could be considered suitable for measurable residual disease (MRD) evaluation in peripheral blood. In the context of the GEM2012MENOS65 and GEM2014MAIN trials, we compared the performance of QIP-MS in serum with next-generation flow (NGF) cytometry in bone marrow to assess MRD in paired samples obtained postinduction, transplant, consolidation and after 24 cycles of maintenance. At each time point, both NGF and QIP-MS were able to segregate 2 groups of patients with significantly different progression-free survival; when the evolution of the results obtained with either method was considered, maintaining or converting to MRD negativity was associated with longer survival, significantly better when compared with sustaining or converting to MRD positivity.
View Article and Find Full Text PDFArticle Synopsis
- CAR T-cell therapies have improved the detection of M-protein in patients with relapsed/refractory multiple myeloma (RRMM), even when traditional methods fail.
- Quantitative immunoprecipitation mass spectrometry (QIP-MS) provides highly sensitive measurements of serum M-protein and can identify interferences from monoclonal antibody therapies.
- QIP-MS showed a high level of agreement with serum immunofixation, but less so with bone marrow-based flow cytometry, and it appears to be a valuable non-invasive tool for monitoring treatment responses in multiple myeloma patients.